DescriptionAberrant activation of MET, a receptor tyrosine kinase (RTK), leads to tumor growth, invasion and metastasis and is implicated in multiple types of cancers. Hence, various strategies have been employed to target MET for cancer therapy including recombinant form of MET ectodomain to sequester ligand and suppress MET activity. Here, we describe multiple C-terminal truncated MET decoys receptors (sdMET) with therapeutic potential. We show that these sdMET isoforms are translated from stable mRNA variants which are generated via Intronic polyadenylation (IPA) of MET’s pre-mRNA in a U1-snRNP (U1) dependent manner. Moreover, we demonstrate increase in sdMET IPA isoforms of choice at expense of full-length MET with our antisense-based strategy by blocking U1 binding to specific 5’ splice site and activating downstream intronic poly (A) site. Our strategy is an improvement of current methods due to its two-pronged approach: suppress MET activity in targeted cells by converting oncogenic MET into soluble decoy to have dominant negative effect on surround microenvironment in paracrine manner.